Appeals Court Reinstates FDA Restrictions on Abortion Pill Access
A U.S. appeals court froze FDA rules allowing telehealth and mail-order mifepristone dispensing.
Why it matters: The ruling halts nationwide access to mifepristone by mail or telehealth, setting up a Supreme Court fight and requiring in-person clinic visits. Legal teams advising health systems, telemedicine providers, and compliance functions must reassess risk and protocols amid shifting federal drug policy.
- On May 1, 2026, the 5th Circuit Court of Appeals stayed FDA rules for telehealth and mailing mifepristone.
- The ruling reinstates pre-2016 FDA regulations requiring in-person clinic dispensing.
- Case: Alliance for Hippocratic Medicine v. FDA, led by Louisiana and several states.
- Lawyers anticipate an emergency Supreme Court appeal following this decision.
The Fifth Circuit Court of Appeals on May 1, 2026, issued its order in Alliance for Hippocratic Medicine v. FDA, cutting off the Biden-era FDA policies that had allowed telehealth prescription and mail delivery of mifepristone. Clinics must now provide the medication in person, reviving requirements first established in the FDA’s 2000 approval and maintained until changes in 2016 and later years.
- The court’s opinion—written by Judge Kyle Duncan—highlighted state interests in regulating abortion, quoting Louisiana's argument: "Every abortion facilitated by FDA’s action cancels Louisiana’s ban on medical abortions and undermines its policy that 'every unborn child is [a] human being.'"
- The American College of Obstetricians and Gynecologists reported that medication abortion accounted for 63% of U.S. abortions in 2023, indicating the broad impact of the FDA rule changes.
- Julia Kaye, staff attorney at the ACLU, warned in remarks to AP News that the order affects “patients' access to abortion and miscarriage care in every state in the nation.”
The cycle of state-led legal challenges to FDA authority has accelerated since Dobbs v. Jackson Women’s Health Organization (2022), with this order reflecting growing jurisdictional tension between state abortion bans and federal drug safety policy.
In-house legal departments—especially in health care, pharmacy, and telemedicine—must consider new compliance risks, as the nationwide ruling overrides state-level abortion permissiveness. An emergency Supreme Court stay is widely expected.
Full decision available via Fifth Circuit Opinion PDF.
By the numbers:
- 63% — Share of U.S. abortions using mifepristone in 2023 (American College of Obstetricians and Gynecologists)
- 2016 — Year FDA first relaxed in-person mifepristone dispensing rules
- 13 — Number of states with near-total abortion bans since 2022 (KFF)
Yes, but: Yes, but courts could still temporarily stay this restriction pending a Supreme Court review.
What's next: An emergency application to the U.S. Supreme Court to block the 5th Circuit’s order is expected shortly.